Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Mar 15,2020
Medicilon assisted Zhejiang Bolaatu Medical Technology Co., Ltd on PA1010 tablets with implied permission for clinical trials
On March 10, 2020, PA1010 tablets, which are independently developed by Zhejiang Bolaatu Medical Technology Co., Ltd, obtained the implied license for NMPA clinical trials. This is the first new drug declared by Bolaatu.  PA1010 is a new class I drug for chronic hepatitis B (CHB). Zhejiang Bolaatu is a new drug research and developmentRead more
More
Mar 12,2020
Medicilon’s Oncolytic Virus Services
Recombinant virus genome modification technology has gradually matured, greatly improving the effect, specificity and safety of oncolytic viruses in tumor treatment. Coupled with the mutual benefit of oncolytic viruses and traditional anti-tumor therapies, the prospects of oncolytic viruses are promising. Let us understand the development status of oncolytic viruses together and walk into Medicilon's oncolyticRead more
More
Medicilon’s Oncolytic Virus Services
Mar 05,2020
Attacking with virus-oncolytic virus
Late nineteenth century A 42-year-old woman with leukemia suddenly recovered after a suspected infection with influenza virus. 1912 Italian doctors reported a case in which a patient with advanced cervical cancer had a significant remission after injection of rabies vaccine. The above seemingly bizarre cases have opened up new ideas for tumor immunity, that is,Read more
More
Attacking with virus-oncolytic virus
Feb 26,2020
Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon
Guangzhou Magpie Pharmaceuticals announced the clinical trials of MN-08, a treatment for Idiopathic Pulmonary Artery Hypertension (IPAH).  IPAH is a progressive disease that affects the precapillary pulmonary vasculature.  IPAH is a rare and fatal disease which has a high mortality rate. During the collaboration between Magpie Pharmaceuticals and Medicilon, Medicilon completed the research and developmentRead more
More
Feb 10,2020
Medicilon – Extraordinary "2 0 1 9”
In 2019, Medicilon has had an extraordinary year. The steadily developing Medicilon made a huge accumulation in 2019 and achieved a qualitative leap.  Let us look back on the moments of glory and Extraordinary "2 0 1 9”. 2 – Double Happiness I Listed on Sci-Tech Innovation Board in Shanghai On Nov. 5th 2019, ShanghaiRead more
More
Medicilon – Extraordinary "2 0 1 9”
Jan 13,2020
Medicilon was awarded "2019 Excellent Listed Enterprise" at ZJ Science City Annual Event
Medicilon was awarded "2019 Excellent Listed Enterprise” for its remarkable innovation and advances in the year 2019, at ZJ Science City Annual Event in Jan. 10th, 2020. This award showcased the huge progress Medicilon has made since going public in 2019 and would inspire Medicilon to keep the momentum in 2020 and achieve bigger success.Read more
More
Jan 10,2020
Practical Strategy and Key Points of Establishing Drug PK Analysis Method Based on Competitive ELISA
The classic technology of ELISA has many years of development history. There are many types of methods. Competitive ELISA technology is one of the basic types. Like sandwich ELISA technology, it is also applied to drug PK analysis and research; how to be based on competitiveness The principle of ELISA to construct a competitive AssayRead more
More
Practical Strategy and Key Points of Establishing Drug PK Analysis Method Based on Competitive ELISA
Dec 19,2019
Medicilon is selected for 2019 Influential Science and Technology Startup Company
On December 18, 2019, Medicilon, with the outstanding innovation ability, was honored with one of the "Influential Science and Technology Startup Company” issued by Zhangjiang Science and Technology Investment during the 2019 Zhangjiang Science and Technology Investment Annual Exchange Conference with the theme "π Infinite · Creation of the Future”.  It is understood that theRead more
More
Medicilon is selected for 2019 Influential Science and Technology Startup Company
Dec 12,2019
Medicilon´s IND Filing-Innovative Drug Research and Development
On December 9-10, 2019, the "Fifth Pharmaceutical Frontier Summit Forum” was held concurrently during the "Nanjing International Life and Health Technology Expo”, with the theme of "Leading Life Science and Technology, Empowering the Health Industry”, through academician reports and round tables Dialogues, special exchanges, exhibitions and other ways to gather innovative resources, focus on theRead more
More
Medicilon´s IND Filing-Innovative Drug Research and Development
Dec 11,2019
BioTianfu -- Medicilon assists in the application of bio-innovative drug research
From December 7th to 8th, 2019, the "2019 BioTianfu Tumor Immunology Industry-University-Research Fusion Innovation Summit Forum and the 20th Interferon and Cytokine Academic Annual Conference" was successfully held in Chengdu, Tianfu.
More
BioTianfu -- Medicilon assists in the application of bio-innovative drug research
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->